January 21, 2026 a 07:31 am
MRK: Dividend Analysis - Merck & Co., Inc.
Merck & Co., Inc. has exhibited robust dividend credentials backed by a long history of continuous dividend payments. With a payout yielding a solid 3.27%, the company demonstrates a stable and sustainable dividend policy, making it an attractive choice for income investors aiming for reliable returns.
📊 Overview
Merck & Co., Inc., operating in the pharmaceutical sector, boasts a commendable dividend yield supported by consistent dividend payments. It has maintained a 56-year long history of divis over which no recent cuts or suspensions have been experienced since 2004.
| Key Metric | Value |
|---|---|
| Sector | Pharmaceuticals |
| Dividend yield | 3.27 % |
| Current dividend per share | 3.10 USD |
| Dividend history | 56 years |
| Last cut or suspension | 2004 |
🗣️ Dividend History
The longstanding continuity of dividends is a testament to Merck's consistent cash flow and profit-generating capabilities. Such a track record boosts investor confidence in its future dividend prospects.
| Year | Dividend per share (USD) |
|---|---|
| 2025 | 3.28 |
| 2024 | 3.12 |
| 2023 | 2.96 |
| 2022 | 2.80 |
| 2021 | 2.61 |
📈 Dividend Growth
Merck's dividend growth indicates a promising trend, reflecting its capacity to enhance shareholder value. This is crucial for long-term investors seeking growth alongside income.
| Time | Growth |
|---|---|
| 3 years | 5.42 % |
| 5 years | 6.75 % |
The average dividend growth is 6.75 % over 5 years. This shows moderate but steady dividend growth.
⚠️ Payout Ratio
Assessing the payout ratios can provide insights into dividend sustainability. Merck's well-adjusted payout ratios indicate a balanced dividend policy with room for reinvestment in growth, aligning shareholder interests strategically.
| Key figure | Ratio |
|---|---|
| EPS-based | 40.64 % |
| Free cash flow-based | 59.27 % |
The EPS-based payout ratio of 40.64 % and the FCF payout ratio of 59.27 % indicate prudent dividend coverage, ensuring both sustainability and growth capacity.
✅ Cashflow & Capital Efficiency
The cash flow metrics are essential in evaluating Merck’s ability to sustain dividend payments and invest in growth. Strong free cash flow and efficient capital allocation are driving factors for long-term success.
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Free Cash Flow Yield | 7.18 % | 3.22 % | 5.24 % |
| Earnings Yield | 6.80 % | 0.13 % | 5.17 % |
| CAPEX to Operating Cash Flow | 15.71 % | 29.70 % | 22.98 % |
| Stock-based Compensation to Revenue | 1.19 % | 1.07 % | 0.91 % |
| Free Cash Flow / Operating Cash Flow Ratio | 84.29 % | 70.30 % | 77.02 % |
Merck's efficient capital allocation and strong free cash flow underpin its dividend capabilities and ensure room for strategic investments, maintaining a balance between growth and shareholder returns.
📉 Balance Sheet & Leverage Analysis
Merck's balanced leverage and strong liquidity ratios point to a robust financial position, essential for sustained dividend growth and profitability.
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Debt-to-Equity | 82.63 % | 96.51 % | 69.55 % |
| Debt-to-Assets | 32.68 % | 34.00 % | 29.30 % |
| Debt-to-Capital | 45.25 % | 49.11 % | 41.02 % |
| Net Debt to EBITDA | 0.97 | 4.26 | 0.91 |
| Current Ratio | 1.36 | 1.25 | 1.47 |
| Quick Ratio | 1.15 | 1.00 | 1.23 |
| Financial Leverage | 2.53 | 2.84 | 2.37 |
Overall, Merck's leverage remains well-contained, supporting its strategic objectives and ensuring financial resilience.
🛠️ Fundamental Strength & Profitability
A robust fundamental profile with strong margins and adequate returns on equity and assets suggests that Merck is generating efficient returns on its investments.
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Return on Equity | 36.96 % | 0.97 % | 31.57 % |
| Return on Assets | 14.62 % | 0.34 % | 13.30 % |
| Margins: | |||
| Net | 26.68 % | 0.61 % | 24.49 % |
| EBIT | 33.05 % | 5.05 % | 29.36 % |
| EBITDA | 40.06 % | 11.49 % | 35.95 % |
| Gross | 76.32 % | 73.17 % | 70.63 % |
| R&D to Revenue | 25.30 % | 50.79 % | 22.85 % |
Merck's strong return metrics illustrate its core profitability, backed by consistent reinvestment in R&D to support long-term innovation and growth.
📈 Price Development
📝 Dividend Scoring System
| Criteria | Score | |
|---|---|---|
| Dividend yield | 4 | |
| Dividend Stability | 5 | |
| Dividend growth | 4 | |
| Payout ratio | 4 | |
| Financial stability | 4 | |
| Dividend continuity | 5 | |
| Cashflow Coverage | 4 | |
| Balance Sheet Quality | 4 |
Total Score: 34/40
🏆 Rating
Given its impressive history of dividend payments, consistent growth, and robust financial fundamentals, Merck & Co., Inc. emerges as a strong candidate for dividend-focused portfolios. Suitable for investors seeking stability with growth potential.